Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

NCT01276639 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01276639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01276639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2011
Completion date
April 30, 2013
Enrollment
901 (actual)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis